Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. (February 2012)

• Record Type: Journal Article
• Authors: Zhang, Min; Garbuzenko, Olga B; Reuhl, Kenneth R; Rodriguez-Rodriguez, Lorna; Minko, Tamara
• Is Part Of: Nanomedicine. Volume 7:Number 2(2012)
• Page Start: 185
• Page End: 197
• Publication Date: 2012-02
• Subjects: antisense oligonucleotides targeted to MDR1 and BCL2 mRNA -- cisplatin -- doxorubicin -- LHRH receptor-specific targeting -- liposomes -- multicomponent nanosystem -- primary and metastatic ovarian cancer -- suppression of drug resistance; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm.11.131
• Languages: English
• ISSNs: 1743-5889

Abstract

Aims: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects.Materials & Methods: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma.Results: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects.Conclusions: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.